A Phase II Study of R-CHOP [rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone] and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
- 01 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 01 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov.